Boston BioCom was co-founded by Partners HealthCare System and received a value-added investment from Pfizer Inc. The involvement of Partners clinical institutions significantly elevates the level of analytic sophistication and biological erudition applied to the company's commercial development efforts, providing an important clinical perspective to technology development. Pfizer provides the company an important pharma industry perspective on emerging technologies it selects for development. Boston BioCom benefits from these relationships as it advances innovations toward key commercial milestones. Pfizer is represented on the Corporate Board of Managers, Operating Committee, and Scientific Advisory Board. Boston BioCom has entered into a collaborative agreement with Maxwell Biotech Venture Fund, one of the first Russian Biotech funds, to assist each other in sourcing and developing mutual opportunities.

Click on the logos below to find out more